Therabionic

Therabionic is a medical technology company specializing in the development of non-invasive treatments for advanced cancers using low-level radiofrequency electromagnetic fields (RF-EMF). The company's flagship product, the TheraBionic P1, is a portable, home-use device that delivers tumor-specific frequencies via a mouthpiece antenna to produce a systemic anti-tumor effect. In 2024, the TheraBionic P1 received FDA De Novo clearance for the treatment of patients with advanced hepatocellular carcinoma (HCC) who have progressed on or are intolerant to systemic therapies. Beyond HCC, the company is conducting clinical trials to evaluate the efficacy of its RF-EMF technology in other solid tumors, including breast, ovarian, and prostate cancers. Therabionic's approach represents a novel modality in oncology, aiming to provide a safe and effective alternative or adjunct to traditional systemic treatments.